OncoMatch/Clinical Trials/NCT07419295
A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)
Is NCT07419295 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments for bladder cancer.
Treatment: Rescue medications for chemotherapy · Sacituzumab tirumotecan · Vinflunine · Docetaxel · Paclitaxel · Rescue medications for sacituzumab tirumotecan — Researchers are looking for new ways to treat locally advanced or metastatic urothelial cancer (UC). Current treatments for locally advanced or metastatic UC include chemotherapy, immunotherapy, and targeted therapy. Researchers want to know if giving sacituzumab tirumotecan (sac-TMT), the trial medicine, can treat locally advanced or metastatic UC that got worse after certain treatments. The goal of this trial is to learn if people who receive sac-TMT live longer than those who receive certain non-platinum chemotherapies.
Check if I qualifyExtracted eligibility criteria
Cancer type
Urothelial Carcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: anti-PD-L1 therapy
Has received treatment with anti-programmed cell death [ligand] 1 (anti-PD-[L]1) therapy
Must have received: platinum-based chemotherapy
Has received treatment with ... platinum-based chemotherapy
Must have received: antibody-drug conjugate (enfortumab vedotin)
Has received treatment with ... enfortumab vedotin (EV)
Cannot have received: antibody-drug conjugate (trophoblast cell-surface antigen 2 (TROP2)-targeted ADC)
Has received prior therapy with trophoblast cell-surface antigen 2 (TROP2)-targeted antibody drug conjugate (ADC)
Cannot have received: antibody-drug conjugate (topoisomerase 1 inhibitor-containing ADC)
Has received prior therapy with a topoisomerase 1 inhibitor-containing ADC
Cannot have received: chemotherapy (paclitaxel, docetaxel, vinflunine)
Has received prior chemotherapy for urothelial cancer with any of the study therapies in the control arm (paclitaxel, docetaxel, and vinflunine)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- TriHealth Cancer Institute-Good Samaritan Hospital ( Site 0822) · Cincinnati, Ohio
- Thompson Cancer Survival Center ( Site 0803) · Knoxville, Tennessee
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify